Skip to main content
Publications
Polo R, Garcia-Albeniz X, Teran C, Morales M, Rial-Crestelo D, Garcinuno MA, Garcia del Toro M, Hita C, Gomez-Sirvent JL, Buzon L, Diaz de Santiago A, Perez Arellano JL, Sanz J, Bachiller P, Martinez Alfaro E, Diaz-Brito V, Masia M, Hernandez-Torres A, Guerra J, Santos J, Arazo P, Munoz L, Arribas JR, Martinez de Salazar P, Moreno S, Hernan MA, del Amo J. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers. Clin Microbiol Infect. 2022 Aug 5;1198-743X(22):00370-6. doi: 10.1016/j.cmi.2022.07.006.
Fernandez-Hidalgo N, Ferreria-Gonzalez I, Marsal JR, Ribera A, Aznar ML, de Alarcon A, Garcia-Cabrera E, Galvez-Acebal J, Sanchez-Espin G, Reguera-Iglesias JM, De La Torre-Lima J, Lomas JM, Hidalgo-Tenorio C, Vallejo N, Miranda B, Santos-Ortega A, Castro MA, Tornos P, Garcia-Dorado D, Almirante B. A pragmatic approach for mortality prediction after surgery in infective endocarditis: optimizing and refining EuroSCORE. Clin Microbiol Infect. 2018 Oct;24(10):1102. doi: 10.1016/j.cmi.2018.01.019
Vaz LE, Kleinman KP, Kawai AT, Jin R, Kassler WJ, Grant PS, Rett MD, Goldmann DA, Calderwood MS, Soumerai SB, Lee GM. Impact of Medicare's Hospital-Acquired Condition policy on infections in safety net and non-safety net hospitals. Infect Control Hosp Epidemiol. 2015 Jun;36(6):649-55. doi: 10.1017/ice.2015.38.
Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res. 2011 Jun 15;17(12):4063-70. doi: 10.1158/1078-0432.CCR-10-2599
LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox A, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res. 2003 Jun 1;9(6):2040-8.